Drugs / Cridanimod
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02064725 | Sep 2014 → Jan 2018 | endometrial carcinoma | Kevelt AS | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2016-08-19 | Xenetic Biosciences, Inc. | Regulatory Xenetic Biosciences Announces FDA Acceptance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of Virexxa® in Endometrial Cancer xeneticbio.com ↗
This enables Xenetic to initiate a Phase 2 clinical study of Virexxa in conjunction with progestin therapy for the treatment of endometrial cancer in women with recurrent or persistent disease who have failed progestin monotherapy. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-08-19 | Xenetic Biosciences, Inc. | Xenetic Biosciences Announces FDA Acceptance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of Virexxa® in Endometrial Cancer xeneticbio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cridanimod | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02064725 ↗ |
| Modality | Small molecule | — CHEMBL1569545 ↗ |
| Route | Intramuscular | “administered sodium cridanimod (500 mg i.m./ twice a week)” NCT02064725 ↗ |